Latest News & Events
LEXINGTON, Mass., February 02, 2022, PR NEWSWIRE – Hemanext Inc. (“Hemanext” or the “Company”), a...
Hemanext ONE Becomes First Blood Processing and Storage System to Receive Standards-Compliant Seal from AABB
LEXINGTON, Mass., January 24, 2022, PR NEWSWIRE – Hemanext Inc. today announced that Hemanext...
Innovative Blood Processing and Storage System Received CE Mark Certification for Sale in European...
Hemanext successfully closes series a equity funding round, bringing total raised to more than $100 million
Leading Blood Storage Innovator Expanded Series A Round to Accommodate Interest from Noted Private...
Current and prospective investors access to the investor Portal
COVID 19 Updates
Follow the course of COVID-19 and locate where to donate blood
View educational material and interesting presentations
Numerous studies pertaining to clinical implications of storage lesion suggest a linkage to hyper-coagulability, inflammation, impaired perfusion, immuno-modulation, organ dysfunction13, and mortality14.